Insights from immuno-oncology

April 1, 2020


Photo by Pixabay from Pexels

The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. It is becoming apparent that the ‘ground glass’ infiltrative appearance seen on CT scans from patients with COVID-19 with pneumonitis is reminiscent of imaging from patients with immune checkpoint inhibitor (ICI)-induced pneumonitis.1 2 Additionally, elevated interleukin-6 (IL-6) is a hallmark inflammatory signature seen in serum of patients with severe COVID-19 acute respiratory distress.3 Many of us have experience with the administration of immune-modulatory agents, which is why the cancer immunotherapy community is poised to contribute to the current fight against COVID-19.

Read the full article here.

Previous Article
NEJM: First Case of 2019 Novel Coronavirus in the United States
NEJM: First Case of 2019 Novel Coronavirus in the United States

This report covers the first case of 2019-nCoV infection confirmed in the United States and describes the i...

Next Article
Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic
Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic

This document identifies the potential risks of exposure to patients, allied health care staff, industry re...